Countable Labs Raises $26 Million in Latest Funding Round
Countable Labs, a company based in Palo Alto, California, has successfully raised $26 million in an undisclosed funding round. The financing was led by ARCH Venture Partners with additional investments from F-Prime Capital and Primer Ventures. This round of funding aims to accelerate the commercialization and global expansion of Countable Labs' key product, the Countable PCR technology.
Cutting-edge Genomics Technology
Countable Labs specializes in precision genomics research by counting DNA molecules with single-molecule precision. Their Countable PCR technology is designed to offer unmatched sensitivity and accuracy, surpassing traditional digital PCR methods. The technology is particularly beneficial for applications in genomics where high sensitivity and precision are critical.
Strategic Use of Funds
The newly acquired funds will primarily support the development of solutions that leverage Countable PCR’s unique capabilities. These include applications in cell and gene therapy, minimal residual disease testing, biomarker validation, vaccine quality control, and molecular diagnostics.
Additionally, the funding will facilitate Countable Labs' international commercial expansion. The company has appointed Christopher Citraro as the Vice President of Global Sales to lead this initiative. Citraro brings nearly two decades of experience in life sciences sales, having held leadership roles at companies such as 10x Genomics and Thermo Fisher Scientific.
Leadership Insights
Giovanna Prout, CEO and Board Member of Countable Labs, emphasized the importance of this funding for the company's future. "2026 is a critical year for Countable Labs’ momentum. This financing gives us the resources to ensure every laboratory that could benefit from a more sensitive genomics measurement solution finds Countable PCR," Prout stated. She highlighted the robustness of the technology and the need to market new products for key segments like cell and gene therapy.
Looking Ahead
With this substantial investment, Countable Labs is poised to make significant strides in the genomics field. The focus on developing fit-for-purpose solutions and expanding their global reach marks a pivotal step in their growth strategy. As the company continues to innovate, the support from leading investors underscores confidence in Countable Labs' potential to transform genomics research and applications.